Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug Candidate

Icon Bioscience Completes Enrollment in Phase I Study of Novel Ophthalmic Drug
Candidate
-Trial to Examine New Therapeutic Platform in Patients with Cystoid Macular
Edema-

SUNNYVALE, Calif., Aug. 5 /PRNewswire/ -- Icon Bioscience, Inc., (IBI), a
privately held ophthalmic pharmaceutical company, announced today that
enrollment has been completed in its Phase I clinical trial to assess the
safety and efficacy of its lead product, IBI-20089, in patients with cystoid
macular edema. This multi-site trial enrolled patients with cystoid macular
edema associated with retinal vein occlusion and post operative cataract
surgery.
IBI-20089 is a novel drug product based on IBI's proprietary Verisome(TM)
drug delivery platform technology, which is optimally suited for application
in the ophthalmic market. IBI-20089 is designed to last up to one year with
a single intravitreal injection. It uniquely provides physicians the
flexibility to tailor the duration of effect for a particular patient. IBI-
20089 is administered as a standard intravitreal injection without the need
for additional devices or surgical procedures.
"We are pleased to have reached this important milestone. Our preliminary
data confirms the safety and efficacy of our lead product, IBI-20089, as well
as the versatility and flexibility of our underlying Verisome(TM) drug
delivery technology," said Vernon G. Wong, MD, Founder of Icon Bioscience,
Inc. "We believe IBI is creating the future standard of ophthalmic care as
evidenced by the development of IBI-20089, the first of many products already
in development based on the Verisome(TM) technology."
About Icon Bioscience, Inc.
Icon Bioscience, Inc. (IBI) is a privately held company focused on the
development and commercialization of novel ophthalmic pharmaceuticals, based
on its proprietary Verisome(TM) drug delivery platform. The Verisome(TM) drug
delivery technology encompasses over twenty related but distinct novel and
proprietary drug delivery systems optimally suited for application in the
ophthalmic market. The nature of ophthalmic disease and the unique anatomical
and physiological features of the eye, combined with the extreme fragility of
the eye, dictate that identifying the correct pharmaceutical agent for a
specific disease state represents only half the solution. The pharmaceutical
agent must be delivered in a manner that maximizes clinical efficacy while
minimizing costs and adverse effects. IBI's lead product, IBI-20089, is in
Phase I clinical trials for the treatment of cystoid macular edema.
Contact: Icon Bioscience, Inc.
William S. (Sandy) White
Phone: 408-734-8188 Ext. 14
Email: sandywhite@iconbioscience.com

SOURCE Icon Bioscience, Inc.

William S. (Sandy) White of Icon Bioscience, Inc., +1-408-734-8188, ext. 14,
sandywhite@iconbioscience.com